Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

                   
yahoo.com     May 22, 2008            

COLLEGEVILLE, Pa. & TARRYTOWN, N.Y.----Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc. , today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR™ . [read full story]                

Full Coverage
                   

Wyeth and Progenics Announce Preliminary Clinical Trial Results for Relistor Oral and Intravenous...

drugs.com     May 22, 2008          

COLLEGEVILLE, Pa. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 22, 2008 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials... ... COLLEGEVILLE, Pa. &...                

comments

                   

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

redorbit.com     May 22, 2008          

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR(TM) (methylnaltrexone bromide).                

comments

Market Review: Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral...

tmcnet.com     May 23, 2008          

Streetinvesting.com has now resumed our progressive Wyeth (NYSE:WYE) as it fell down $0.31 on below average volume early trading Thursday, May 22, 2008. Wyeth Pharmaceuticals, a division of Wyeth and Progenics Pharmaceuticals, Inc. announced preliminary results from two clinical trials conducted...                

comments

                   

Wyeth And Progenics Announce Preliminary Clinical Trial Results For RELISTOR Oral And Intravenous...

medicalnewstoday.com     May 23, 2008          

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR(TM) (methylnaltrexone bromide).                

comments

                   

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

webwire.com     May 23, 2008          

WEBWIRE – Friday, May 23, 2008 Collegeville, Pa., and Tarrytown, N.Y. — Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc. , today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR™...                

comments